Today’s Research Reports on Trending Tickers: Global Blood Therapeutics and Cara Therapeutics

NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 percent to close at 24,117.59, while the S&P 500 Index fell 0.86 percent to close at 2,699.63. The Nasdaq Composite Index declined 1.54 percent to close at 7,455.09.

“To a certain degree, investors are looking for something to be worried about. Stocks aren’t far from all-time highs, and for a lot of people that’s hard to justify,” said Dan Wantrobski, director of research at Janney Montgomery Scott. “However, I think volatility is returning to the U.S. market and that we could see another correction cycle. I’m not calling for a structural downturn, but tariffs and trade wars could exacerbate the weakness,” Wantrobski added.

RDI Initiates Coverage on:

Global Blood Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=GBT

Cara Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=CARA

Global Blood Therapeutics’ stock jumped 15.63% Wednesday, to close the day at $44.75. The stock recorded a trading volume of 16,672,218 shares, which was above its three months average volume of 786,529 shares. In the last year, Global Blood Therapeutics’ shares have traded in a range of 24.02 – 68.05. The share price has gained 86.3% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $46.23 is below its 200-day moving average of $49.44. Shares of Global Blood Therapeutics have fallen roughly 4.07 percent in the past month and are up 13.72 percent year-to-date.

Access RDI’s Global Blood Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GBT

On Wednesday, shares of Cara Therapeutics recorded a trading volume of 11,571,331 shares, which was above the three months average volume of 1,017,764 shares. The stock ended the day 9.85% higher at $18.06. The share price has fallen 35.61% from its 52 week high with a 52 week trading range of 11.11 – 28.05. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $15.02 is above its 200-day moving average of $13.57. Shares of Cara Therapeutics have gained roughly 6.11 percent in the past month and are up 47.55 percent year-to-date.

Access RDI’s Cara Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CARA

Our Actionable Research on Global Blood Therapeutics, Inc. (NASDAQ :GBT) and Cara Therapeutics, Inc. (NYSE :CARA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504003